tetano
Editor, Senior Moderator
PLoS One. 2019 Jan 25;14(1):e0209643. doi: 10.1371/journal.pone.0209643. eCollection 2019.
[h=1]Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.[/h] Yun JW[SUP]1[/SUP], Choi MJ[SUP]1[/SUP], Shin GS[SUP]2[/SUP], Lim JO[SUP]2[/SUP], Noh JY[SUP]1[/SUP], Kim YK[SUP]3[/SUP], Song JY[SUP]1[/SUP], Kim WJ[SUP]1[/SUP], Choi SE[SUP]2[/SUP], Cheong HJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] Despite a high vaccine uptake rate of over 80% in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV).
[h=4]METHODS:[/h] A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and ≥85 years), and the at-risk group was studied.
[h=4]RESULTS:[/h] Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV.
[h=4]CONCLUSIONS:[/h] The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.
PMID: 30682030 DOI: 10.1371/journal.pone.0209643
Free full text
[h=1]Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.[/h] Yun JW[SUP]1[/SUP], Choi MJ[SUP]1[/SUP], Shin GS[SUP]2[/SUP], Lim JO[SUP]2[/SUP], Noh JY[SUP]1[/SUP], Kim YK[SUP]3[/SUP], Song JY[SUP]1[/SUP], Kim WJ[SUP]1[/SUP], Choi SE[SUP]2[/SUP], Cheong HJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] Despite a high vaccine uptake rate of over 80% in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV).
[h=4]METHODS:[/h] A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and ≥85 years), and the at-risk group was studied.
[h=4]RESULTS:[/h] Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV.
[h=4]CONCLUSIONS:[/h] The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.
PMID: 30682030 DOI: 10.1371/journal.pone.0209643
Free full text